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Zinc finger nucleases(ZFNs) and transcription activator-like effector 
nucleases (TALENs) , engineered nucleases, are composed of designable 
DNA-binding domains and a non-specific nuclease domain and enable a 
broad range of genomic modification by inducing double-strand breaks 
(DSBs) that stimulate intrinsic cellular repair mechanisms such as non-
homologous recombination (NHEJ) and homologous recombination (HR) 
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at specific genomic locations. This technology has been described earlier 
as promising tools for targeted genome engineering in cells and many 
organisms. Recently, RNA-guided endonucleases (RGENs) derived from 
bacterial type-II CRISPR/Cas system, have been described as site-specific 
endonucleases whose specificities are programmed by small RNA 
components. RGEN also has been applied in cells and organisms as 
genome engineering tool. Here in this study, injection of RGENs as Cas9 
protein: guide RNA complexes or Cas9 mRNA plus guide RNA into one-
cell stage embryos of mice and zebrafish efficiently disrupts a target gene 
in both species. RGENs efficiently generated germ-line transmittable 
mutations in up to 93% of newborn mice with minimal toxicity. RGEN-
induced mutations in the mouse Prkdc gene that encodes an enzyme 
critical for DNA double strand break repair resulted in immunodeficiency 
both in F0 and F1 mice. I propose that RGEN-mediated mutagenesis in 
animals will greatly expedite the creation of genetically-engineered model 
organisms accelerating functional genomic research. 
Keywords: RNA-guided endonucleases (RGENs),Cas9, guide RNA, 
Knockout  
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The clustered regularly interspaced short palindromic repeat 
(CRISPR)–CRISPR-associated (Cas) system induces an adaptive immune 
response against invading phages and plasmids in bacteria and archea 
(Wiedenheft et al. 2012). Cas9, a protein derived from Streptococcus 
pyogenes, is complexed with CRISPR RNA (crRNA), whose sequence is 
originated from phages and plasmids, and trans-activating crRNA 
(tracrRNA) to form an active DNA-cleaving endonuclease whose 
specificity is determined by Watson-Crick base-pairing between crRNA 
and target DNA of 20 base pairs (bp) in length and by the NGG-
trinucleotide protospacer adjacent motif (PAM) recognized by Cas9. A 
single-guide RNA (sgRNA) generated by fusing crRNA and tracrRNA is 
also functional and can reprogram Cas9 protein to cleave a specific DNA 
sequence (Figure. 1) (Jinek et al. 2012). Thus, Cas9 is an RNA-guided 
endonuclease (RGEN) that protects microbial cells from invading phages 
and plasmids by digesting their DNA site-specifically, reminiscent of 
restriction endonuclease-mediated protection of host cells from foreign 
genetic elements. Unlike restriction endonucleases, however, the Cas9 
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specificity is readily reprogrammed by replacing crRNA, making these 
nucleases ideal tools for genome engineering in higher eukaryotic cells 
and organisms. 
Recent studies have shown that Cas9-derived RGENs is, indeed, 
a new member in the growing family of genome editing nucleases 
(Bassett et al. 2013; Chang et al. 2013; Cho et al. 2013a; Cong et al. 2013; 
DiCarlo et al. 2013; Friedland et al. 2013; Hwang et al. 2013b; Jiang et al. 
2013; Jinek et al. 2013; Mali et al. 2013; Shen et al. 2013; Wang et al. 
2013; Xiao et al. 2013), which include zinc finger nucleases (ZFNs) and 
transcription activator-like effector nucleases (TALENs). These 
programmable nucleases induce site-specific DNA double-strand breaks 
(DSBs) in cells, whose repair via high-fidelity homologous recombination 
or error-prone non-homologous end-joining (NHEJ) gives rise to targeted 
mutations (Bibikova et al. 2003; Kim et al. 2009; Kim et al. 2010; Miller 
et al. 2010) or chromosomal rearrangements (Brunet et al. 2009; Lee et al. 
2009; Lee et al. 2011). For example, Shen et al. (2013) demonstrated that 
RGENs induced mutations in a reporter gene in transgenic mouse lines. 
Wang et al. (2013) used RGENs to induce multiple mutations in a single 
step in mice. Although these initial pioneering results are encouraging, it 
is unknown whether and how efficiently the RGEN-induced mutations 
detected in embryos or pups can be transmitted to the next generation, a 
process required for the establishment of gene-knockout (KO) animals. 
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Here, This studies show that the injection of Cas9 protein complexed with 
guide RNA or Cas9 mRNA plus guide RNA into one-cell embryos gives 






















II. Materials and Methods  
 
1. RGEN components.  
 
Cas9 mRNA and sgRNAs were synthesized in vitro from linear 
DNA templates using the mMESSAGE mMACHINE T7 Ultra kit 
(Ambion) and MEGAshortscript T7 kit (Ambion), respectively, according 
to the manufacturers’ instructions, and were diluted with appropriate 
amounts of diethyl pyrocarbonate (DEPC, Sigma)–treated injection buffer 
(0.25 mM EDTA, 10 mM Tris, pH 7.4). Templates for sgRNA synthesis 
were generated using oligonucleotides listed in Supplemental Table 5 as 
described previously (Cho et al. 2013a). Recombinant Cas9 protein (Cho 
et al. 2013a) was obtained from ToolGen, Inc. 
 




Restriction enzyme-treated linearized plasmid (5nM) was 
incubated for 60 min at 37 °C with Cas9 protein (20 nM), and sgRNA (40 
nM) in 1X NEB 3 buffer. Reactions were stopped with 6X stop solution 
containing 30% glycerol, 1.2% SDS, and 100 mM EDTA. Products were 
resolved with 1% agarose gel electrophoresis and were visualized with 
ethidium bromide (EtBr) staining. 
 
3. Microinjection of RGENs into mouse embryos.  
 
All animal experiments were performed in accordance with the 
Korean Food and Drug Administration (KFDA) guidelines. Protocols 
were reviewed and approved by the Institutional Animal Care and Use 
Committees (IACUC) of the Laboratory Animal Research Center at 
Yonsei University (Permit Number: 2013-0099). All mice were 
maintained in the specific pathogen–free facility of the Yonsei Laboratory 
Animal Research Center.  
FVB/NTac (Taconic) and ICR (DBL, Korea) mouse strains were used as 
embryo donors and foster mothers, respectively. Female FVB/NTac mice 
(7–8 weeks old) were super-ovulated by intra-peritoneal injections of 5 IU 
pregnant mare serum gonadotropin (PMSG, Sigma) and 5 IU human 
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chorionic gonadotropin (hCG, Sigma) at 48-hour intervals. The super-
ovulated female mice were mated to FVB/NTac stud males, and fertilized 
embryos were collected from oviducts.  
Cas9 mRNA and sgRNAs in M2 medium (Sigma) were injected into the 
cytoplasm of fertilized eggs with well-recognized pronuclei using a Piezo-
driven micromanipulator (Prime Tech). The recombinant Cas9 protein: 
Foxn1-sgRNA complex was diluted with DEPC-treated injection buffer 
(0.25 mM EDTA, 10 mM Tris, pH 7.4) and injected into male pronuclei 
using a TransferMan NK2 micromanipulator and a FemtoJet microinjector 
(Eppendorf). The manipulated embryos were transferred into the oviducts 
of pseudopregnant foster mothers to produce live animals, or were 
cultivated in vitro for further analyses.  
 
4. Fluorescent PCR. 
 
 100 ng of genomic DNA were amplified by PCR using 5-6-
carboxyfluorescein (6-FAM)-labeled primers (F2) (Supplemental Table 6). 
PCR products were resolved using ABI 3730xl DNA analyzer, and fPCR 





5. Genotyping, sequence analyses, and phenotyping of 
mutant mice.  
 
 To screen F0 mice and in vitro cultivated mouse embryos with 
RGEN-induced mutations, T7E1 assays were performed as previously 
described using genomic DNA samples from tail biopsies and lysates of 
whole embryos (Cho et al. 2013a). Briefly, the genomic region 
encompassing the RGEN target site was PCR-amplified, melted, and re-
annealed to form heteroduplex DNA, which was treated with T7 
endonuclease 1 (New England Biolabs), and then analyzed by agarose gel 
electrophoresis. For the newborn mice that were negative in the T7E1 
assays, additional T7E1 assays were conducted by mixing equal amounts 
of wild-type PCR products. Potential off-target sites were identified by 
searching with Bowtie 0.12.9 (Langmead et al. 2009) and were also 
similarly monitored by T7E1 assays. The primer paired used in T7E1 
assays were represented on Supplemental Tables 6 and 7.  
Mutant founders identified by the T7E1 assay were further analyzed by 
fPCR. For routine PCR genotyping of F1 progenies, the following primer 




CCAGGCCTAGGTTCCAGGTA-3' for the Foxn1 gene, 5'-
CCCCAGCATTGCAGATTTCC-3' and 5'-
AGGGCTTCTTCTCTACAATCACG-3' for Prkdc gene. 
 
6. Characterization of immune cells by flow cytometry. 
 
BALB/c mice were purchased from DBL (Korea), and C.B.-17 
scid mice (C.B-Igh-1b/IcrTac-Prkdcscid) were imported from Taconic. 
Lymphocytes were prepared and processed as previously described (Park 
et al. 2000). PerCP-, APC-, V605-, V421-, PE-Cy7- and PerCP-Cy5.5-
conjugated antibodies specifically detecting CD3e (145-2C11), CD19 
(1D3), CD4 (RM4-5) and CD8 (53-6.7), respectively were purchased 
from BD Biosciences or Biolegend. Flow cytometry was performed with 
FACS Calibur and FACS CantoII (BD Biosciences), and the data was 




7. Procedures of RGEN-mediated mutagenesis in 
zebrafish embryos.  
 
Wild-type and Tg[huC:GFP] transgenic zebrafish were maintained at 
28.5 °C on a 14-hour light/10-hour dark cycle. Embryonic stages were 
determined by the post-fertilization hour and microscopic observation. 
Animal work was approved by the internal animal ethics committee at 
Chungnam National University (CNU-00191). 
One-cell stage zebrafish embryos were injected with the indicated doses 
were incubated at 28.5 °C for the indicated points, and their phenotypes 
and genotypes were examined. Genomic DNA was extracted from 
developing zebrafish embryos using a genomic DNA purification system 
(Promega, USA) following the manufacturer’s instructions. Targeted 
genomic loci were amplified from five pooled embryos using primers 
designed to flank the Cas9 complex target site and cloned into the pGEM 
T-easy vector (Promega, USA); the cloned segments were then sequenced 








1. RGEN Design and Production.  
 
To examine the gene knockout potential of RGENs in pronuclear 
(PN)-stage mouse embryos, I selected the forkhead box N1 (Foxn1) gene, 
which is important for thymus development and keratinocyte 
differentiation (Nehls et al. 1996), and the protein kinase, DNA activated, 
catalytic polypeptide (Prkdc) gene, which encodes an enzyme critical for 
DNA DSB repair and recombination (Taccioli et al. 1998). I designed 
several sgRNAs specific to exon 2 in the Foxn1 gene (Figure. 2a) and 
exon 2 in the Prkdc gene (Figure. 3aB). First, I tested the in vitro DNA-
cleavage activities of RGENs composed of synthetic sgRNA and 
recombinant Cas9 protein expressed in and purified from E. coli (Figure. 
2b and Figure. 3b). The Foxn1- and Prkdc-specific sgRNAs that 
manifested the highest activities were chosen for the subsequent in vivo 




2. Generation of Founder Mice with RGEN-induced 
Mutations. 
 
To evaluate the genome-editing activity of the Foxn1-RGEN, I  
injected Cas9 mRNA (10 ng/l solution) with various doses of the sgRNA 
into the cytoplasm of PN-stage mouse embryos, and conducted T7 
endonuclease I (T7E1) assays (Kim et al. 2009) using genomic DNAs 
obtained from in vitro cultivated embryos (Figure. 4a). Mutant fractions 
(the number of mutant embryos/the number of total embryos) were dose-
dependent, ranging from 31% (1 ng/l sgRNA) to 87% (100 ng/l) 
(Figure. 4b). Sequence analysis confirmed mutations in the Foxn1 gene; 
most mutations were small deletions (Figure. 4c), reminiscent of those 
induced by ZFNs and TALENs (Kim et al. 2013b). Notably, 
approximately 90% of the RGEN-injected embryos developed to 
blastocysts and then hatched from the zona pellucida, suggesting that 
RGENs were not cytotoxic under these experimental conditions (Figure. 
4b).  
Encouraged by the high mutant frequencies and low cytotoxicity 
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induced by RGENs, I produced live animals by transferring the mouse 
embryos into the oviducts of pseudo-pregnant foster mothers (Figures. 5a-
c and Table 1). Notably, the birth rates were very high, ranging from 58% 
to 73%, and were not affected by the increasing doses of Foxn1-sgRNA 
(Table 1). Out of 147 newborns, I obtained 99 mutant founder mice (Table 
1). Consistent with the results observed in cultivated embryos (Figure. 4b), 
mutant fractions were proportional to the doses of Foxn1-sgRNA, and 
reached up to 93% (100 ng/l Foxn1-sgRNA) (Table 1). To generate 
Prkdc-targeted mice and to test whether higher doses of RGENs are 
tolerated in embryos, I applied a 5-fold higher concentration of Cas9 
mRNA (50 ng/l) with increasing doses of Prkdc-sgRNA (50, 100, and 
250 ng/l). Again, the birth rates were very high, ranging from 37% to 
60%, enough to produce a sufficient number of newborns for the analysis 
(Fig. 6 and Table 1). The mutant fraction was 57% (21 mutant founders 
among 37 newborns) at the maximum dose of Prkdc-sgRNA (Table 1). 
These birth rates obtained with RGENs were approximately 2- to 10-fold 
higher than those obtained with TALENs targeting two unrelated genes, 
which were reported in our previous study (Sung et al. 2013), on par with 
those of transgenic mouse production (Nagy et al. 2003). These results 
demonstrate that RGENs are potent gene-disrupting reagents with 
minimal toxicity.  
Fluorescent PCR (Schuelke 2000) (fPCR; Figure. 5b and Figure. 
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6b, Tables 2 and 3) and Sanger sequencing analyses (Figure. 5c and 
Figure. 6c, Tables 4-5) revealed distinct characteristics of RGEN-induced 
mutations in founder mice. Most Foxn1 mutants were mosaic (22 out of 
33 founders, 67%), and exhibited up to 5 alleles (founder #66), indicating 
that the RGEN activity persisted later than the first cleavage of one-cell 
embryos (Table 2). Notably, 9 mice (27%) harbored bi-allelic mutations 
with no wild-type allele. Similar mosaic patterns were also observed in 
Prkdc mutant mice (20/39 founders, 51%; Table 3). In addition, identical 
mutant alleles were often observed for both Foxn1 and Prkdc genes 
(Tables 5-6). For example, I identified 3 founder mice with homozygous 
mutations in the Foxn1 gene (Table 2). 
 
3. Gene Disruption by Cas9 protein-sgRNA Complex 
in Mice and Zebrafish.  
 
Alternatively, I directly injected the RGEN in the form of 
recombinant Cas9 protein harboring a nuclear localization signal (NLS) 
(0.3 to 30 ng/l) complexed with Foxn1-specific sgRNA (0.14 to 14 ng/l) 
into the cytoplasm or pronucleus of one-cell mouse embryos, and 
analyzed mutations in the Foxn1 gene using in vitro cultivated embryos 
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(Figure. 7). These injection doses and methods minimally affected the 
survival and development of mouse embryos in vitro: over 70% of 
RGEN-injected embryos hatched out normally in both experiments. Again, 
mutant fractions obtained with Cas9 protein injection were dose-
dependent, and reached up to 88% at the highest dose via pronucleus 
injection and to 71% via intra-cytoplasmic injection (Figure. 7a and b). 
Similar to the mutation patterns induced by Cas9 mRNA plus sgRNA 
(Figure. 4c), those induced by the Cas9 protein-sgRNA complex were 
mostly small deletions (Figure. 7c). These results clearly demonstrate that 
the proteinaceous RGEN has high gene-disrupting activity in mouse 
embryos. 
I also tested whether proteinaceous RGENs could induce 
mutations in zebrafish embryos. I designed RGENs that target the 
exogenous GFP reporter gene or an endogenous gene, microphthalmia-
associated transcription factor a (mitfa), which encodes a master 
regulator of melanocyte development in vertebrates (Figure. 8a and b) 
(Lister et al. 1999; Park et al. 2000). Injection of up to 8 ng of Cas9 
protein complexed with mitfa-specific sgRNA did not perturb normal 
development in >80% of the embryos (Figure. 9). When embryos were 
injected with Cas9 protein plus mitfa- or GFP-specific sgRNA, mutations 
were detected at target sites in a dose-dependent manner (Figure. 8a and 
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b). A time-course experiment revealed that the Cas9 protein:sgRNA 
complex triggered mutations as early as at 4 hour post-injection stage, 2 
hours faster than did Cas9 mRNA plus sgRNA (Figure. 8c). A subset of 
zebrafish embryos co-injected with Cas9 protein:mitfa-specific sgRNA 
manifested defects in melanocyte development (Figure. 11), 
demonstrating that some of their somatic tissues were nullizygous for the 
mitfa gene. These results indicate that RGENs injected as Cas9 
protein:sgRNA complexes can exert sufficient gene-disrupting activities 
to induce null mutations at both endogenous and exogenous genomic loci 
at an early developmental stage in zebrafish embryos.  
 
4. Analysis of Off-target Effects of RGENs.  
 
I examined whether the RGENs generated off-target mutations in 
the mouse genome. I searched for possible off-target sites that included 1- 
to 3-bp mismatches with the sgRNA target sequence. A total of 4 and 63 
such sites were found for the Foxn1 and Prkdc target sequences, 
respectively, in the entire mouse genome. T7E1 assays were conducted 
using genomic DNA samples from the founder mice obtained with the 
highest doses of Foxn1- and Prkdc-sgRNAs. These founder mice were bi-
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allelic or mosaic mutants (Tables 2 and 3). Even though these mutant 
founders were produced using high levels of RGENs in one-cell embryos, 
no off-target activities were detected in any of the 4 genomic loci that 
were highly homologous with the target sequence of Foxn1-RGEN or any 
of the 6 such sites of the Prkdc-RGEN (Figures. 12 and 13). Of note is the 
absence of T7E1-detectable mutations at sites with a single-base mismatch 
in the putative 11-base seed region near the GG-dinucleotide PAM (e.g., 
Prkdc Off5 and Foxn1 Off3 in Figure. 13 and Figure. 12) or with a perfect 
match in the seed region and 2- or 3-base mismatches upstream of the 
seed region (Prkdc Off3, Off4, and Off6 in Figure. 13).  
 
 
5. Phenotype Analysis and Germ-line Transmission of 
Prkdc-mutant Mice.  
 
Targeted deficiency of Prkdc gene in mice results in severe 
combined immunodeficiency (Taccioli et al. 1998). For the functional 
validation of RGEN-induced mutations of Prkdc gene in mice, I evaluated 
the immunological phenotypes of F0 mutant founders using peripheral 
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blood mononuclear cells (PBMC). The mosaic founder #1 carried a wild-
type allele (Table 3), and showed comparable B and T cell populations to 
those of the wild-type BALB/c mouse (Figure. 14). On the other hand, the 
mutant founder #47 possessed bi-allelic null mutations in the Prkdc gene, 
and these immune cell populations were significantly lowered in the 
PBMC (Figure. 14), indicating the functional loss of Prkdc gene functions.  
To test the germ-line transmission of the mutant alleles of the 
Prkdc gene, I crossed the male founder #25 (Δ269/Δ61/WT) with a female 
founder #33 (Δ4/+2/WT; Table 3), and monitored the genotypes of F1 
offspring (Figure. 15a). As expected, all the progenies were wild-type, or 
inherited one or two mutant alleles from their parents (Figure. 15a). I also 
confirmed the germ-line transmission of Foxn1 mutant alleles from the 
Foxn1 founder #108, and observed the segregation of the mutant alleles in 
the progenies (Figure. 16).  
As expected, the bi-allelic Prkdc mutant progeny showed null 
phenotype (Figure. 15a). Compared to the wild-type BALB/c mouse and 
the progeny #1 carrying a wild-type allele, the bi-allelic mutant progeny 
(#7) exhibited defects in B and T cell populations (Figure. 15b and c). 
Thus, lymphocytes isolated from PBMC and from the primary and 
secondary lymphoid organs including thymus, spleen, and lymph node 
were defective in B and T cell populations (Figure. 15b). Compared to 
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severe combined immunodeficiency (scid) mice, the mutant mouse 
exhibited phenotypic leakiness. For example, the F1 progeny had 1.79% 
CD4+ and 1.07% CD3+ T cells, whereas the T cell populations examined 
were less than 1% in the scid mouse (Figure. 15b). These small 
differences between scid and the bi-allelic mutant mice might reflect the 
differences in their genetic backgrounds, ages, or genotypes. Overall, 
these results clearly proved the functional loss of the Prkdc gene by 





















This study provides strong evidence that RGENs hold great 
promise for generation of knock-out mice and zebrafish. Although there 
were recent reports describing the generation of mutant mice using 
RGENs (Shen et al. 2013; Wang et al. 2013), germline transmission of the 
mutations induced by RGENs has not been confirmed. I showed that 
RGEN-induced mutant alleles were stably transmitted to F1 progenies in 
vertebrate animals, and confirmed the mutant phenotypes using both 
founder mice and F1 mutant progenies. In addition, I also showed that 
recombinant Cas9 protein complexed with sgRNA induced mutations in 
both mice and zebrafish, which potentially broadens the range of the 
RGEN application for in vivo mutagenesis. Nuclease proteins might have 
different kinetics and half-lives in cells, when delivered directly, as 
compared to being produced by gene- or mRNA-mediated expression, 
potentially alleviating off-target effects (Izmiryan et al. 2011; Gaj et al. 
2012). Unlike recombinant ZFNs and TALENs whose purification is 
cumbersome, time-consuming, and laborious, new proteinaceous RGENs 
are prepared simply by mixing Cas9 protein with different sgRNAs or 
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dualRNAs. These features strongly support that RGENs are convenient 
and efficient tools for gene knockout in model organisms. 
The specificity of RGENs is of concern. Because RGENs are 
derived from prokaryotes, whose genomes are much smaller than those of 
higher eukaryotes, RGENs may have off-target effects in animals, plants, 
and cultured human cells such as stem cells. Furthermore, unlike ZFNs 
and TALENs that function as dimers, which enhance specificity, RGENs 
act as monomers. Recent in vitro studies conducted using cell lines have 
provided the evidence of off-target mutations induced by RGENs (Cong et 
al. 2013; Fu et al. 2013) (Hsu et al. 2013; Pattanayak et al. 2013). 
Fortunately, however, In this study, analyses of off-target effects suggest 
that RGENs might not be associated with highly frequent off-target 
mutations in vivo or in clones. Unlike in vitro experiments using cell 
populations, in vivo experiments analyzed individual offspring or clones. 
Off-target mutations present in cell populations can be diluted out in 
individual clones. In addition, some of the rare off-target mutations in the 
founders can be removed during mating. Although it is possible that the 
RGENs induced off-target mutations at sites that are not analyzed in this 
study, our results suggest that RGENs are specific enough to allow 
targeted mutagenesis in the mouse. A careful choice of target sites that 
lack highly homologous sequences elsewhere in the genome should be 
useful for avoiding or minimizing unwanted off-target mutations as much 
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as possible (Hsu et al. 2013; Kim et al. 2013a).  
On the basis of these results, This studies propose that RGEN-
mediated in vivo mutagenesis will greatly expedite the creation of 
genetically-engineered model organisms, and thereby accelerate 
functional genomic research. Recently, three groups (Fujii et al. 2013; 
Hwang et al. 2013a; Li et al. 2013) have independently reported germline 
transmission of RGEN-induced mutations in zebrafish, mice and rats, 
demonstrating broad utility of RNA-guided genome editing in vertebrate 
model organisms. I also note that recent study used proteinaceous RGENs 















Figure 1. A schematic diagram depicting a target-specific single guide 















Figure 2. Generation of sgRNAs targeted to exon 2 of the mouse 
Foxn1 gene. (a) RGEN target sites in the mouse Foxn1 gene. PAMs are 
capitalized, and targets are denoted by black lines. (b) In vitro cleavage assays 
evaluating Foxn1-sgRNAs complexed with recombinant Cas9 protein against a 
linearized plasmid containing target sequences as a substrate. Arrows indicate 












Figure 3. Generation of sgRNAs targeted to exon 2 of the mouse prkdc 
gene. (a) RGEN target sites in exon 2 of the mouse Prkdc gene. PAMs are 
capitalized, and targets are denoted by black lines. (b) In vitro cleavage assays 












Figure 4. Foxn1 gene knockout in mouse embryos by intra-
cytoplasmic injection of Cas9 mRNA and Foxn1-sgRNA. (a) A 
representative result of a T7E1 assay monitoring the mutation rate after injecting 
the highest dose. Arrows indicate bands cleaved by T7E1. (b) A summary of 
T7E1 assay results. Mutant fractions among in vitro cultivated embryos obtained 
after intra-cytoplasmic injection of the indicated RGEN doses are indicated. The 
percentages were calculated using the number in the column to its left as the 
denominator. (c) DNA sequences of Foxn1 mutant alleles identified from a subset 
of T7E1-positive mutant embryos. The target sequence of the wild-type allele is 












Figure 5. RGEN-induced Foxn1 gene knockout in mice. (a) 
Representative T7E1 assays demonstrating gene-disrupting efficiencies of Cas9 
mRNA plus Foxn1-specific sgRNA that were delivered via intra-cytoplasmic 
injection into one-cell stage mouse embryos. Numbers indicate independent 
founder mice generated from the highest dose. Arrows indicate bands cleaved by 
T7E1. (b) fPCR analysis showing mosaic mutations in the founder mice. (c) DNA 








Figure 6. RGEN-induced Prkdc gene disruption in mice. (a) 
Representative T7E1 assays demonstrating mutagenesis efficiencies of Cas9 
mRNA plus Prkdc-specific sgRNA that were delivered via intra-cytoplasmic 
injection into one-cell stage mouse embryos. Numbers indicate independent 
founder mice generated from the highest dose. Arrows indicate bands cleaved by 
T7E1. fPCR results (b) and DNA sequences of mutant alleles (c) observed in 
three Prkdc mutant founders denoted in red in A. The red arrowhead in C 
indicates the cleavage site by the RGEN.  














Figure 7. Foxn1 gene disruption in mouse embryos using the 
recombinant Cas9 protein: Foxn1-sgRNA complex. (a and b) 
Representative T7E1 assay results and their summaries. Embryos were cultivated 
in vitro after they underwent pronuclear (a) or intra-cytoplasmic (b) injection. 
Numbers in red indicate T7E1-positive mutant founder mice. (c) DNA sequences 
of Foxn1 mutant alleles identified from the in vitro cultivated embryos that were 
obtained by the pronucleus injection of recombinant Cas9 protein: Foxn1-sgRNA 
complex at the highest dose. The target sequence of the wild-type allele is 
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Figure 8. RNA-guided mutagenesis in zebrafish embryos. (a and b) 
Target sequences (upper) and RGEN-induced indels detected by T7E1 assays 
(lower). The Cas9 protein-sgRNA complex was microinjected into one-cell stage 
embryos with concentration of 1 ng, 4 ng, or 8 ng per embryo. (c) Time courses 
of Cas9 protein:sgRNA and Cas9 RNA:sgRNA injection into embryos during 























Figure 9. Toxicities of Cas9 protein complexed with mitfa-specific 
sgRNA in zebrafish embryos. The Cas9 protein-sgRNA complex was 
microinjected into one-cell stage embryos with concentration of 1 ng, 4 ng, or 8 
ng per embryo. After one day of injection, the number of normal, deformed, or 













Figure 10. Targeted indel mutations induced by Cas9 protein complex 
at mitfa and GFP reporter gene. The wild-type sequence is shown at the top, 
and target site in blue, and the PAM motif in red; Inserted bases highlighted as 
green. The column on the right indicates the number of inserted or deleted bases. 





















Figure 11. Induction of somatic mitfa mutations by the Cas9 protein 
complex. (a) Un-injected wild-type embryo at 32 hpf. (b) Injection of mitfa Cas9 
protein complex causes a defect in melanocyte development. (a’) and (b’) is a 
high-magnification in black box in (a) and (b), respectively. (c) T7E1 assay of 
wild-type (a) or mitfa Cas9 protein (b)-injected embryo. (d) T7E1 assay of mitfa 
Cas9 protein-injected one-month old embryos. The somatic mitfa mutations 
remain constant in Cas9 protein-injected embryos (#1-#3) by one-month. Arrows 








Figure 12. Analysis of off-target activity of Foxn1-RGEN. T7E1 assays 
were conducted using DNA from the indicated Foxn1 mutant founders. The 
Foxn1 gene and putative off-target sites bearing 1~3-bp mismatches that were 
selected with bowtie 0.12.9 (25) were examined. Homozygous mutants or bi-
allelic mutants containing large insertion are shown in blue (Table 2), mismatched 









Figure 13. Analysis of off-target activity of RGENs in Prkdc-mutant 
founders. T7E1 assays were conducted using genomic DNA samples from the 
indicated Prkdc mutant founders. The Prkdc gene and putative off-target sites 
bearing 1~3-bp mismatches that were selected with Bowtie 0.12.9 (Langmead et 
al. 2009) were examined. Bi-allelic mutants containing large insertion are shown 
in blue (Table 3), mismatched bases in red, and PAM in green; black lines 











Figure 14. Defective immune cell populations in PBMC from a bi-
allelic Prkdc mutant founder #47. (a) Frequency of CD4+ and CD8+ T cells. 
(b) Frequencies of T cells (CD3+) and B cells (CD19+). The abnormal frequencies 
of immune cells were denoted in red. BALB/c and scid mice, positive and 
negative controls for B and T lymphocytes, respectively; Founder #1, mosaic 






Figure 15. Germ-line transmission and mutant phenotypes of the 
Prkdc mutant mouse. (a) Detailed genotypes of F0 mutants (♂25 and ♀33, 
upper panel) and determination of genotypes of their F1 progenies (#1 and #7) by 
fPCR (lower panel). Using lymphocytes isolated from peripheral blood (PBMC), 
lymph node (LN), spleen, and thymus, frequencies of CD4+ and CD8+ T cells (b) 
and those of CD3+ T cells and CD19+ B cells (c) were determined. The abnormal 
frequencies of immune cells were denoted in red. BALB/c and scid mice, positive 











Figure 16. Germ-line transmission of the mutant alleles found in 
Foxn1 mutant founder #108. (a) fPCR results of wild-type and the founder 
mice (upper panel) and the sequences of mutant alleles (lower panel). (b) PCR 
genotyping of F1 progenies derived from crossing Foxn1 founder #108 and wild-
type FVB/NTac. Note the segregation of the mutant alleles found in Foxn1 
founder #108 in the progenies. The number of occurrences of the sequences is 





Table 1. RGEN-mediated gene knockout in FVB/NTac mice. 
 
Percentages were calculated using the number in each column as the numerator 
and the number in the column to its left as the denominator. *After eliminating the 
numbers of pups that were cannibalized at birth, the percentages were calculated 



























10 + 1 76 62 (82) 45 (73) 40 (65) 13 (33) 
10 + 10 104 90 (87) 52 (58) 49 (54) 32 (65) 
10 + 100 100 90 (90) 62 (69) 58 (64) 54 (93) 
Total 280 242 (86) 159 (66) 147 (61) 99 (67) 
Prkdc 
50 + 50 73 58 (79) 35 (60) 33 (57) 11 (33) 
50 + 100 79 59 (75) 22 (37) 21 (36) 7 (33) 
50 + 250 94 73 (78) 37 (51) 37 (51) 21 (57) 
Total 246 190 (77) 94 (49) 91 (48) 39 (43) 
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Table 2. Genotypes of Foxn1 mutant mice.  
 
Underlined alleles were sequenced.  
Alleles in red, detected by sequencing, but not by fPCR. 
*only one clone sequenced. 
**Not determined by fPCR.  
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Table 3. Genotypes of Prkdc mutant mice. 
 
*Not determined by fPCR. 
Underlined alleles were sequenced.  
Alleles in red, detected by sequencing, but not by fPCR. 
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Table 4. DNA sequences of Foxn1 mutant alleles identified from a 










Table 6. Oligonucletide for preparation of in vitro RNA transcription 
template. 
 
a F, forward; R, reverse 
b Sequences complementary to target DNA are shown in blue. The T7 promoter 
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ZFN 및 TALEN은 특정한 DNA 염기서열에 결합하는 단백질 
도메인과 비특이적인 뉴클레아제 도메인으로 구성된 효소로써 
유전체의 원하는 위치를 절단을 유도하여 세포 내부의 유전자 교정 
메커니즘인 Non-homologous recombination (NHEJ)과 
Homologous recombination (HR)을 통해 돌연변이를 유발할 수 있다. 
최근에 개발된 RNA-guided endonucleases (RGENs) 기술은 
박테리아 발견된 뉴클레아제 효소로써 작은 RNA 분자에 의해 서열 
특이성을 조절 할 수 있는 유전자 가위이고, 지금까지 다양한 cell과 
organism에 대해 적용되어 왔다.  
이번 연구에서는 RGEN을 Cas9 단백질과 guide RNA 복합체 또는 
Cas9 mRNA와 guide RNA를 mice와 zebrafish의 수정란에 
주입함으로써 원하는 유전자를 성공적으로 knockout 할 수 있는 것을 
확인하였다. RNA 가위를 이용한 방법 유전자 교정 방법은 최대 
태어난 mice의 93%가 돌연변이를 가지고 있는 정도로 높은 유전자 
교정효율을 보였을 뿐만 아니라 수정란에서 독성을 보이지 않는 것을 
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확인하였다. 또한 RNA 가위를 통해 세포내의 유전자교정 기작에 
관여하는 효소를 암호화하고 있는 유전자인 prkdc를 손상시킴으로써 
태어난 mice와 자손 mice에 면역결핍증상이 나타나는 것을 확인 
하였다. 또한 유전자 가위를 통해 얻어진 돌연변이가 유전자가위를 
주입을 통해 태어난 mice 뿐만 아니라 교배를 통해 다음세대로 전달이 
가능한 것을 보였다. 이러한 연구 결과를 통해 RNA가위를 이용한 
돌연변이 유발 방법이 동물에서도 효과적인 유전자 교정 기술로 적용 
될 수 있을 것이고, 앞으로 유전체 연구를 좀 더 가속화 할 수 있는 
수단으로 활용 될 것으로 전망할 수 있다. 
 
주요어: RNA-guided endonucleases(RGENs), Cas9, guide 
RNA, Knockout  
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